Updates in the Management of CIDP: The Pharmacist's Role in Individualizing Care, featuring a Patient Perspective

Updates in the Management of CIDP: The Pharmacist's Role in Individualizing Care, featuring a Patient Perspective is organized by Pharmacy Times Continuing Education (PTCE).,Release date: August 29, 2022,Expiration date: August 29, 2023,Description:,Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disorder that affects the peripheral nervous system and can lead to sensory impairment or disease-related disability. The treatment for CIDP centers on decreasing the clinical burden and reducing symptoms so patients may retain functional ability. Immunoglobulin (Ig) is frequently selected as initial therapy for patients with CIDP and is available in intravenous (IV) and subcutaneous (SC) formulations. This activity will review administration implications and dosing considerations specific to IVIg and SCIg formulations for specialty pharmacists and patients. Expert panelists will share perspectives and clinical experiences in individualizing therapy to ensure patient safety as well as best practices in switching IVIg to SCIg therapy. A patient perspective interview incorporated throughout the program will highlight the experience of an individual living with CIDP, including a discussion of challenges surrounding diagnosis and access to treatment.,Educational Objectives,At the completion of this activity, participants will be able to:,• Express the clinical burden of chronic inflammatory demyelinating polyneuropathy (CIDP) to effectively incorporate current treatment strategies and emerging therapeutic approaches,• Identify a place in therapy and best practices for the transition of intravenous immunoglobulin to subcutaneous immunoglobulin among patients with CIDP,• Investigate new and emerging treatment options for CIDP based on the latest safety and efficacy data, relevant clinical evidence, and individualized needs of the patient,• Explain aspects of care in which pharmacists can be involved to optimize outcomes for patients with CIDP